Targeting renal cell carcinoma with a HIF-2 antagonist
2016 · Nature · 704 citations
https://doi.org/10.1038/nature19796
J
James P. Rizzi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
2.9K
Citations
20
h-index
23
i10-index
James P. Rizzi is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Acute Myeloid Leukemia Research & Cancer, Hypoxia, and Metabolism & Chronic Myeloid Leukemia Treatments. The author has an h-index of 20, co-authored 48 publications.
Papers by this author
worksOn-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 · Nature · 448 citations
https://doi.org/10.1038/nature19795
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
2016 · Cancer Research · 316 citations
https://doi.org/10.1158/0008-5472.can-16-0473
3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
2019 · Journal of Medicinal Chemistry · 202 citations
https://doi.org/10.1021/acs.jmedchem.9b00719
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat